Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05544240
Other study ID # Phase 1 SV-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date February 1, 2023
Est. completion date December 31, 2024

Study information

Verified date May 2024
Source Williams Cancer Foundation
Contact Jason Williams, MD
Phone (954) 530-4606
Email dr@williamscancerinstitute.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 31, 2024
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Male or female, aged >18 years old at the time of signed informed consent 2. Provide written informed consent and must be willing to adhere with treatment and follow-up. 3. Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor who have not responded or progressed after standard therapies or for whom no further standard therapy exists or standard therapy is not available. 4. Meet all eligibility criteria 5. Has undergone a cardiac work-up and received cardiac clearance two months before first treatment 6. Has halted use of any anticoagulants or other blood thinners (including but not limited to heparin or warfarin) within five (5) days of each treatment. 7. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) v5 grade = 1. 8. Measurable disease by RECIST. 9. Able to undergo general anesthesia or conscious sedation. 10. Eastern Cooperative Oncology Group (ECOG) performance status of < 3. 11. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the study.Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must be on stable doses for at least 42 days prior to the cryolysis 12. In the opinion of the Investigator, there is no other meaningful life-prolonging therapy option available. 13. Adequate bone marrow, renal, and hepatic function, defined as follows: a. Bone marrow function without transfusion 30 days before first dosing: i. Absolute neutrophil count = 1.5 x 109/L; Lymphocyte count of = 1.0 x 109/L; Platelet count = 100 x 109/L; ii. Hemoglobin = 9.0 g/dL b. Renal function: i. Estimated glomerular filtration rate =30 mL/min/1.73 m2 or creatinine clearance calculated by Cockcroft-Gault equation =30 mL/ c. Hepatic function: i. Alanine aminotransferase = 3x upper limit of normal (ULN) ii. Aspartate aminotransferase = 3x ULN iii. Total bilirubin = ULN or total bilirubin = 1.5x ULN with direct bilirubin = ULN of the laboratory in subjects with documented Gilbert's Syndrome iv. Patients with liver metastases =5x ULN 14. All clinically relevant toxicities related to prior anticancer therapy must have recovered to Grade =1 or baseline (except alopecia or ototoxicity 15. All subjects with female partners of childbearing potential must use effective contraception throughout study treatment and for 120-150 days (4-5 months) after the last dose of study intervention 16. Has at least one lesion that is demonstrable on PET/CT, CT, Ultrasound, or MRI and is accessible for injection Exclusion criteria: 1. Has a known additional malignancy that is progressing or has required active treatment in the last 3 years, excluding basal and squamous cell carcinoma 2. Has undergone major surgery within 28 days prior to enrollment and has not recovered adequately from the toxicities and/or complications 3. Has an active infection (including tuberculosis) requiring systemic therapy 4. Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis 5. Has received a live vaccine within 30 days prior to enrollment 6. Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first treatment 7. Has tumor volume or disease burden too great to provide for safe and/or effective treatment as determined by the Principal Investigator after consultation with Syncromune's Chief Medical Officer 8. Subjects who have metastases limited to subcutaneous regions (only skin) 9. Significant cardiac or other medical illness such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia (e.g., New York Heart Association Class 4), or history of previous heart failure. 10. Malignant pleural effusions or ascites that require immediate intervention 11. Prior history of autoimmune disease except hypothyroidism 12. Any primary or acquired immunodeficiency 13. Active COVID infection or tests positive for COVID day before or day of planned treatment 14. Known or suspected hepatitis B if active infection (subjects with chronic hepatitis B infection must have an undetectable Hepatitis B virus (HBV) viral load on suppressive therapy, if indicated; positive surface antibody alone is not an exclusion) 15. Known or suspected hepatitis C infection which has not been treated and cured unless currently on treatment with an undetectable viral load 16. Prior history of autoimmune disease except hypothyroidism, uncontrolled or unmanaged diabetes, cardiac arrhytmia (unstable or untreated), hypersensitivity, or other illness or disease that in the opinion of the Principal Investigator, with consultation with Syncromune's Chief Medical Officer, makes the subject a poor candidate.Any condition(s) that, in the opinion of the Investigator, would increase the risk for toxicities from study drug, interfere with subject compliance or conduct of this study

Study Design


Intervention

Drug:
SV-101
SV-101 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Locations

Country Name City State
Mexico Hospital Diomed Mexico City

Sponsors (2)

Lead Sponsor Collaborator
Williams Cancer Foundation Syncromune, Inc.

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antitumor activity To assess the preliminary antitumor activity of SV-101 as measured by RECIST 1.1 and iRECIST 4-6 weeks after each treatment
Secondary To evaluate rate of adverse events (AEs), including serious adverse events (SAEs) and AEs leading to treatment discontinuation Safety assessment will include protocol-specified periodic physical examination findings, vital signs, ECOG performance status, protocol-specified laboratory variables (e.g. hematology, coagulation tests, serum chemistry, urine tests), AEs using CTCAE v5.1, and SAEs. Beginning at baseline and including pre-intervention/procedure and through study completion over 1 year period
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients